Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Happle-Tinschert syndrome (HTS) is a rare, sporadic, multisystem disorder characterized by hypo- and hyperpigmented skin patches following Blaschko's lines, plus acral skeletal and other abnormalities and is characterized by basaloid follicular hamartomas. HTS is caused by a postzygotic mutation in the SMO gene (c.1234C>T, p.Leu412Phe).
No clinical trials have been registered for Happle-Tinschert syndrome.
1 publication has been identified in PubMed for Happle-Tinschert syndrome. Research spans Case Report / Case Series (100%).
Rodríguez-Sanchez B (2026). [PMID: 41566980](https://pubmed.ncbi.nlm.nih.gov/41566980/). *Clinical and experimental pediatrics*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 6:51 AM UTC
Common questions about Happle-Tinschert syndrome